

## EARLY TERMINATIONS GRANTED—Continued

[12/01/2020 12:00:00 a.m., 12/31/2020 12:00:00 a.m.]

## 12/28/2020

20210205 .....	G	Caesars Entertainment, Inc.; William Hill PLC; Caesars Entertainment, Inc.
20210689 .....	G	Biogen Inc.; Sage Therapeutics, Inc; Biogen Inc.
20210690 .....	G	Thoma Bravo Fund XIII-A, L.P.; Venafi, Inc; Thoma Bravo Fund XIII-A, L.P.
20210691 .....	G	Nasdaq, Inc.; Verafin Holdings, Inc.; Nasdaq, Inc.

## 12/31/2020

20210651 .....	G	Stephen Griggs; AdaptHealth Corp.; Stephen Griggs.
20210652 .....	G	SkyKnight Aero Holdings, LLC; AdaptHealth Corp.; SkyKnight Aero Holdings, LLC.
20210653 .....	G	Peloton Equity AeroCare SPV I, L.P.; AdaptHealth Corp.; Peloton Equity AeroCare SPV I, L.P.

**FOR FURTHER INFORMATION CONTACT:**

Theresa Kingsberry (202–326–3100),  
Program Support Specialist, Federal  
Trade Commission Premerger  
Notification Office, Bureau of  
Competition, Room CC–5301,  
Washington, DC 20024.

By direction of the Commission.

**April J. Tabor,**

*Secretary.*

[FR Doc. 2021–03183 Filed 2–17–21; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—Funding Opportunity Announcement (FOA), RFA OH–21–003, Extension of the World Trade Center Health Registry (U50); Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—Funding Opportunity Announcement (FOA), RFA OH–21–003, Extension of the World Trade Center Health Registry (U50), April 13, 2021; 9:00 a.m.–6:00 p.m., EDT in the original FRN.

The virtual meeting was published in the **Federal Register** on Monday, January 11, 2021, Volume 86, Number 6, page 1976.

The meeting on April 13, 2021 is being amended to change the time and should read as follows:

*Time:* 1:00 p.m.–3:00 p.m., EDT.

The meeting is closed to the public.

**FOR FURTHER INFORMATION CONTACT:**

Marilyn Ridenour B.S.N., M.B.A.,  
M.P.H., C.P.H., C.I.C., CAPT, USPHS,  
Scientific Review Officer, CDC, National  
Institute for Occupational Safety and  
Health, 1095 Willowdale Road, Mailstop

1811, Morgantown, West Virginia  
26505, Telephone (304) 285–5879.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit,  
Office of the Chief Operating Officer, Centers  
for Disease Control and Prevention.*

[FR Doc. 2021–03231 Filed 2–17–21; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Advancing Translational Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Advancing Translational Sciences Special Emphasis Panel; CTSA Revision Award.

*Date:* March 9, 2021.

*Time:* 12:00 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1078, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Rahat (Rani) Khan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1078, Bethesda, MD 20892, 301–894–7319 [khanr2@csr.nih.gov](mailto:khanr2@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: February 11, 2021.

**David W. Freeman,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021–03190 Filed 2–17–21; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Autologous Therapy for the Treatment of Autoimmune Disease Using Chimeric Antigen Receptors Targeting CD19

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Kyverna Therapeutics (“Kyverna”) located in Berkeley, CA.